FI59022C - Foerfarande foer framstaellning av prostaglandin e2 eller dess derivat innehaollande frystorkat pulver - Google Patents
Foerfarande foer framstaellning av prostaglandin e2 eller dess derivat innehaollande frystorkat pulver Download PDFInfo
- Publication number
- FI59022C FI59022C FI760800A FI760800A FI59022C FI 59022 C FI59022 C FI 59022C FI 760800 A FI760800 A FI 760800A FI 760800 A FI760800 A FI 760800A FI 59022 C FI59022 C FI 59022C
- Authority
- FI
- Finland
- Prior art keywords
- prostaglandin
- frystorkat
- innehaollande
- pulver
- foerfarande foer
- Prior art date
Links
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 title description 11
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 title description 9
- 229960002986 dinoprostone Drugs 0.000 title description 5
- 150000003180 prostaglandins Chemical class 0.000 description 23
- 239000000243 solution Substances 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 10
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 10
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 10
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 229960000711 alprostadil Drugs 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000004108 freeze drying Methods 0.000 description 6
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000008176 lyophilized powder Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- WGJJROVFWIXTPA-OALUTQOASA-N prostanoic acid Chemical compound CCCCCCCC[C@H]1CCC[C@@H]1CCCCCCC(O)=O WGJJROVFWIXTPA-OALUTQOASA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- -1 hydroxy fatty acids Chemical class 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 235000020079 raki Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2515001 | 1975-04-04 | ||
| DE2515001A DE2515001C2 (de) | 1975-04-04 | 1975-04-04 | Prostaglandin enthaltende gefriergetrocknete Pulver |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI760800A7 FI760800A7 (cg-RX-API-DMAC7.html) | 1976-10-05 |
| FI59022B FI59022B (fi) | 1981-02-27 |
| FI59022C true FI59022C (fi) | 1981-06-10 |
Family
ID=5943206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI760800A FI59022C (fi) | 1975-04-04 | 1976-03-25 | Foerfarande foer framstaellning av prostaglandin e2 eller dess derivat innehaollande frystorkat pulver |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US4058623A (cg-RX-API-DMAC7.html) |
| JP (1) | JPS5940147B2 (cg-RX-API-DMAC7.html) |
| BE (1) | BE840357A (cg-RX-API-DMAC7.html) |
| CH (1) | CH637375A5 (cg-RX-API-DMAC7.html) |
| DE (1) | DE2515001C2 (cg-RX-API-DMAC7.html) |
| DK (1) | DK146435C (cg-RX-API-DMAC7.html) |
| FI (1) | FI59022C (cg-RX-API-DMAC7.html) |
| FR (1) | FR2305972A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB1540483A (cg-RX-API-DMAC7.html) |
| IE (1) | IE42671B1 (cg-RX-API-DMAC7.html) |
| LU (1) | LU74695A1 (cg-RX-API-DMAC7.html) |
| NL (1) | NL183439C (cg-RX-API-DMAC7.html) |
| SE (1) | SE427006B (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA787353B (en) * | 1978-05-17 | 1980-08-27 | Wellcome Found | Pharmaceutical formulations |
| US4301146A (en) * | 1980-07-29 | 1981-11-17 | G. D. Searle & Co. | Stabilization of 16-oxygenated prostanoic acid derivatives |
| DE3162914D1 (en) * | 1981-01-10 | 1984-05-10 | Chinoin Gyogyszer Es Vegyeszet | Stabilized prostaglandin tablets for topical use with regulated dissolving speed and process for preparing them |
| US4675182A (en) * | 1983-02-12 | 1987-06-23 | Bayer Aktiengesellschaft | Complexes of prostaglandins |
| US4835320A (en) * | 1986-06-03 | 1989-05-30 | Societe Francaise Hoechst | Process for the preparation of glyoxal monoactals |
| US4857711A (en) * | 1988-08-16 | 1989-08-15 | Illinois Tool Works Inc. | Positive temperature coefficient heater |
| JPH02149353U (cg-RX-API-DMAC7.html) * | 1989-05-22 | 1990-12-19 | ||
| JPH03107251U (cg-RX-API-DMAC7.html) * | 1989-06-30 | 1991-11-05 | ||
| DE4125255A1 (de) * | 1991-07-31 | 1993-02-04 | Knoll Ag | Prostaglandin e (pfeil abwaerts)1(pfeil abwaerts)-formulierung |
| CA2222811C (en) * | 1995-06-01 | 2008-09-30 | G.D. Searle & Co. | Stabilized solid dispersions of misoprostol |
| AU4218400A (en) * | 1999-04-05 | 2000-10-23 | Emisphere Technologies, Inc. | Lyophilized solid dosage forms and methods of making |
| US20090035260A1 (en) * | 2002-07-29 | 2009-02-05 | Therapicon Srl | Enhanced nasal composition of active peptide |
| ITMI20040235A1 (it) * | 2004-02-13 | 2004-05-13 | Therapicon Srl | Preparazione farmaceutica per il cavo orale |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3069322A (en) * | 1958-05-28 | 1962-12-18 | Bergstrom Sune | Pge and pgf |
| US3644638A (en) * | 1970-08-24 | 1972-02-22 | American Home Prod | Compositions and methods for relieving bronchial spasm with prostanoic acids and esters |
| FR2157899A1 (en) * | 1971-10-22 | 1973-06-08 | Upjohn Co | 16-mono and di-lower alkyl prostaglandin compsns - - for treatment of peptic ulcers |
| US3904679A (en) * | 1972-05-23 | 1975-09-09 | Upjohn Co | 15-Methyl and 15-ethyl prostaglandin F{HD 2{331 {0 {B analogs |
| US3826823A (en) * | 1972-09-25 | 1974-07-30 | Syntex Inc | Stabilized prostaglandin preparations |
| US3954787A (en) * | 1974-06-18 | 1976-05-04 | Pfizer Inc. | Stabilized E-series prostaglandins |
-
1975
- 1975-04-04 DE DE2515001A patent/DE2515001C2/de not_active Expired
-
1976
- 1976-03-22 US US05/669,336 patent/US4058623A/en not_active Expired - Lifetime
- 1976-03-23 NL NLAANVRAGE7603043,A patent/NL183439C/xx not_active IP Right Cessation
- 1976-03-25 FI FI760800A patent/FI59022C/fi not_active IP Right Cessation
- 1976-03-25 DK DK131976A patent/DK146435C/da not_active IP Right Cessation
- 1976-03-29 SE SE7603741A patent/SE427006B/xx not_active IP Right Cessation
- 1976-03-30 CH CH396276A patent/CH637375A5/de not_active IP Right Cessation
- 1976-04-02 FR FR7609599A patent/FR2305972A1/fr active Granted
- 1976-04-02 LU LU74695A patent/LU74695A1/xx unknown
- 1976-04-02 IE IE701/76A patent/IE42671B1/en unknown
- 1976-04-02 BE BE165827A patent/BE840357A/xx not_active IP Right Cessation
- 1976-04-05 GB GB13689/76A patent/GB1540483A/en not_active Expired
- 1976-04-05 JP JP51038124A patent/JPS5940147B2/ja not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| IE42671B1 (en) | 1980-09-24 |
| NL7603043A (nl) | 1976-10-06 |
| SE427006B (sv) | 1983-02-28 |
| CH637375A5 (de) | 1983-07-29 |
| NL183439C (nl) | 1988-11-01 |
| SE7603741L (sv) | 1976-10-05 |
| FI760800A7 (cg-RX-API-DMAC7.html) | 1976-10-05 |
| GB1540483A (en) | 1979-02-14 |
| FR2305972B1 (cg-RX-API-DMAC7.html) | 1979-09-21 |
| DE2515001A1 (de) | 1976-10-14 |
| JPS5940147B2 (ja) | 1984-09-28 |
| DE2515001C2 (de) | 1986-10-02 |
| JPS51127048A (en) | 1976-11-05 |
| BE840357A (fr) | 1976-10-04 |
| FI59022B (fi) | 1981-02-27 |
| DK131976A (da) | 1976-10-05 |
| LU74695A1 (cg-RX-API-DMAC7.html) | 1976-11-11 |
| IE42671L (en) | 1976-10-04 |
| US4058623A (en) | 1977-11-15 |
| DK146435C (da) | 1984-03-26 |
| FR2305972A1 (fr) | 1976-10-29 |
| NL183439B (nl) | 1988-06-01 |
| DK146435B (da) | 1983-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI59022C (fi) | Foerfarande foer framstaellning av prostaglandin e2 eller dess derivat innehaollande frystorkat pulver | |
| US4663316A (en) | Antibiotic clathrates and pharmaceutical compositions thereof | |
| FI61807B (fi) | Foerfarande foer stabilisering av meningokockpolysackarid | |
| US5051402A (en) | Pharmaceutical composition containing cyclosporin in admixture with α- | |
| JPH0336827B2 (cg-RX-API-DMAC7.html) | ||
| US5080906A (en) | Method and composition for oral administration of n-acetylcysteine | |
| HU228338B1 (en) | Pharmaceutical formulations containing voriconazole | |
| IE904711A1 (en) | The Use of Inclusion Complexes of Prostaglandins with¹Cyclodextrins in the Treatment of Ocular Hypertension | |
| HU215920B (hu) | Eljárás cisztinszármazékokat tartalmazó, immunstimuláns hatású gyógyszerkészítmények előállítására | |
| KR100198046B1 (ko) | 사이클로덱스트린과 니메설리드의 포접 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물 | |
| CA1297407C (en) | Pharmaceutical which can be administered nasally, a process for it preparation, and its use | |
| KR830000527B1 (ko) | 프로스타사이클린 화합물 제제의 안정화방법 | |
| CN1046516C (zh) | 化合物dx－52－1的稳定方法和其冻干组合物 | |
| CA1134820A (en) | Triethyl citrate solutions of pge-type compounds | |
| JPS587610B2 (ja) | テトラサイクリントトリス （ ヒドロキシメチル ） アミノメタン トノ フクゴウタイ ノ セイゾウホウホウ | |
| JPH07157431A (ja) | 安定なプロスタグランジンｅ製剤 | |
| WO1986004504A1 (fr) | Clathrates de 9-halogene prostaglandine et leur utilisation comme medicaments | |
| FI90824B (fi) | Menetelmä kylmäkuivattujen farmaseuttisten fenyylikinoliinikarboksyylihappokoostumusten valmistamiseksi | |
| RU2049467C1 (ru) | Антибактериальный, противовоспалительный препарат | |
| FR2682598A1 (fr) | Compositions pharmaceutiques de peptides et procedes pour leur preparation. | |
| ITRM970241A1 (it) | Preparazione farmaceutica fluida a base di nimesulide per uso orale e rinofaringeo | |
| US3885041A (en) | Antiinflammatory use of prostaglandins | |
| JPH07267863A (ja) | プロスタグランジンまたはその類縁化合物を含有する注射用組成物 | |
| FI63036C (fi) | Foerfarande foer framstaellning av fungicida megluminkomplex av polyenmakrolidantibiotika | |
| JPS631318B2 (cg-RX-API-DMAC7.html) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed | ||
| MM | Patent lapsed |
Owner name: SCHERING AKTIENGESELLSCHAFT |